{"id":46995,"date":"2022-08-05T17:02:19","date_gmt":"2022-08-05T15:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/epro-e-patient-diaries-and-ecoa-global-market-report-2022-shift-towards-decentralized-virtual-clinical-trials-to-boost-growth-researchandmarkets-com\/"},"modified":"2022-08-05T17:02:19","modified_gmt":"2022-08-05T15:02:19","slug":"epro-e-patient-diaries-and-ecoa-global-market-report-2022-shift-towards-decentralized-virtual-clinical-trials-to-boost-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/epro-e-patient-diaries-and-ecoa-global-market-report-2022-shift-towards-decentralized-virtual-clinical-trials-to-boost-growth-researchandmarkets-com\/","title":{"rendered":"ePRO, E-Patient Diaries and eCOA Global Market Report 2022: Shift Towards Decentralized\/Virtual Clinical Trials to Boost Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “ePRO, E-Patient Diaries and eCOA – Global Market Trajectory & Analytics”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGlobal ePRO, E-Patient Diaries and eCOA Market to Reach US$2.8 Billion by the Year 2026<\/strong>\n<\/p>\n

\nThe ePRO or eCOA platform offers significant benefits as it mitigates costs, reduces trial times, and reduces administrative burden. It is possible to standardize accurate studies with eCOA. Government regulations mandate the maintenance of EHR (Electronic Health Records). Electronic devices and mobile technologies are being increasingly used in the healthcare sector. Electronic devices are being harnessed to collect and report clinical outcomes.\n<\/p>\n

\nUsers benefit from the data interpretation offered by eCOA products when compared with traditional paper-based resources. This is due to a better quality of information gathering as well as harmonized data systems. Growth in the global market is set to be fueled by increasing pressure on medical device, pharmaceutical and biotechnology companies for improving the productivity, reducing costs, and expediting the process of drug development.\n<\/p>\n

\nGrowth in the market is also being driven by the continuous rise in demand for clinical trials and research studies to develop new drugs, therapies and vaccines. Specifically, the COVID-19 pandemic has led to increased focus by pharma companies and clinical study companies on development of new therapies, vaccines and drugs for managing COVID-19 infection. Faster trial implementation, real-time data sharing, and increased visibility became more relevant during the development of vaccines against SARS-CoV-2.\n<\/p>\n

\nAlso, since there are more people using smartphones, therefore there is greater acceptability of eCOA and ePRO methods. However, need for Internet connectivity, lack of patient awareness about these advanced technologies and shortage of sufficiently skilled persons with technical know-how inhibit the growth and expansion of the market. Concerns about data privacy are another inhibiting factor, with technology advancements and clinical communication and collaborative solutions raise concerns about privacy and security.\n<\/p>\n

\nAmid the COVID-19 crisis, the global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$2.8 Billion by 2026, growing at a CAGR of 14.3% over the analysis period.\n<\/p>\n

\nThe U.S. Market is Estimated at $563.4 Million in 2022, While China is Forecast to Reach $326.9 Million by 2026<\/strong>\n<\/p>\n

\nThe ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$563.4 Million in the year 2022. The country currently accounts for a 35.58% share in the global market. China, the world’s second largest economy, is forecast to reach an estimated market size of US$326.9 Million in the year 2026 trailing a CAGR of 17.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR while Rest of European market (as defined in the study) will reach US$387.2 Million by the end of the analysis period. Developed regions of North America and Europe account for a significant share of the market owing to rise in the number of clinical trials.\n<\/p>\n

\nKey Topics Covered:<\/strong>\n<\/p>\n

\nI. METHODOLOGY<\/strong>\n<\/p>\n

\nII. EXECUTIVE SUMMARY<\/strong>\n<\/p>\n

\n1. MARKET OVERVIEW<\/strong>\n<\/p>\n

\n2. FOCUS ON SELECT PLAYERS<\/strong>\n<\/p>\n

\n3. MARKET TRENDS & DRIVERS<\/strong>\n<\/p>\n